RCT: Rivaroxaban does not have an impact on disease progression and symptoms resolution in high-risk adults with mild COVID-19. 17 Sep, 2021 | 10:19h | UTC Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19 – Clinical Infectious Diseases
Open access
Open access